drugset / Trial / NCT04000698
Personalized Targeted Preparative Regimen Before T-depleted Allogeneic HSCT in Children With Chemoresistent Acute Leukemias
Phase 3
Unknown
25 enrolled
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and efficiency of personalized targeted therapy in combination with high-dose chemotherapy as part of a preparative regimen before T-depleted allogeneic hematopoietic stem cell transplantation in children with chemoresistant acute leukemias
Timeline
- Start
- 2019-10-15
- Primary completion
- 2022-07
- Completion
- 2022-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Abatacept | Other / unclassified | — | — |
| Background | Cytarabine | Small molecule | — | — |
| Background | Daratumomab | Unknown | — | — |
| Background | Fludarabin | Unknown | — | — |
| Background | Plerixafor | Small molecule | — | — |
| Background | Rituximab | Monoclonal antibody | — | — |
| Background | Tocilizumab | Monoclonal antibody | — | — |
| Background | Treosulfan | Small molecule | — | — |
| Background | Vecanoid | Unknown | — | — |
| Background | Venetoclax | Small molecule | — | — |
| Background | thiophosphomide | Unknown | — | — |